GUIDELINES FOR THE USE OF
TOPOCAL MORPHINE FOR
PAINFUL SKIN ULCERS IN
PALLIATIVE CARE

Policy Details

<table>
<thead>
<tr>
<th>NHFT document reference</th>
<th>MMG029</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version</td>
<td>Version 1 – November 2012</td>
</tr>
<tr>
<td>Date Ratified</td>
<td>07.12.12</td>
</tr>
<tr>
<td>Ratified by</td>
<td>Medicines Management Committee</td>
</tr>
<tr>
<td>Implementation Date</td>
<td>07.12.12</td>
</tr>
<tr>
<td>Responsible Director</td>
<td>Medical Director</td>
</tr>
<tr>
<td>Review Date</td>
<td>07.12.14</td>
</tr>
<tr>
<td>Related Policies &amp; other documents</td>
<td>MMP001 – Control of Medicines Policy</td>
</tr>
<tr>
<td>Freedom of Information category</td>
<td>Guideline</td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS

1. DOCUMENT CONTROL SUMMARY .......................................................... 3
2. INTRODUCTION ..................................................................................... 4
3. PURPOSE ............................................................................................... 4
4. DEFINITIONS .......................................................................................... 4
5. DUTIES .................................................................................................... 4
  5.1. The Medicine Management Committee .......................................... 4
  5.2. Unit Managers ................................................................................. 5
  5.3. Doctors ........................................................................................... 5
  5.4. Nursing staff .................................................................................... 5
6. PROCESS ............................................................................................... 5
  6.1. Inclusion Criteria ............................................................................. 5
  6.2. Exclusion Criteria ............................................................................ 5
  6.3. Cautions .......................................................................................... 5
  6.4. Contraindications ............................................................................ 6
  6.5. Adverse Effects ................................................................................ 6
  6.6. Guidelines for the Use of Topical Morphine .................................... 6
    6.6.1. Prescribing .............................................................................. 6
    6.6.2. Dose and frequency of application ..................................... 6
    6.6.3. Secondary dressing ............................................................ 7
    6.6.4. Monitoring........................................................................... 7
    6.6.5. Preparation ............................................................................ 7
    6.6.6. Stability .................................................................................. 7
    6.6.7. Disposal.............................................................................. 8
7. TRAINING ............................................................................................... 8
  7.1. Mandatory Training ......................................................................... 8
  7.2. Specific Training not covered by Mandatory Training ................. 8
8. MONITORING COMPLIANCE WITH THIS DOCUMENT ......................... 8
9. REFERENCES AND BIBLIOGRAPHY .................................................... 9
10. RELATED TRUST POLICY ................................................................. 9
APPENDIX 1 – TREATMENT ALGORITHM ................................................ 10
APPENDIX 2 – TREATMENT PROCEDURE .............................................. 11
1. DOCUMENT CONTROL SUMMARY

<table>
<thead>
<tr>
<th>Document Title</th>
<th>Guidelines for the Use of Topical Morphine for Painful Skin Ulcers in Palliative Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Purpose (executive brief)</td>
<td>To provide guidance on the use of topical morphine for painful skin ulcers in Palliative Care</td>
</tr>
<tr>
<td>Status: - New / Update/ Review</td>
<td>New</td>
</tr>
<tr>
<td>Areas affected by the policy</td>
<td>Inpatient hospice areas</td>
</tr>
<tr>
<td>Policy originators/authors</td>
<td>Melanie Harvey – Staff Nurse Cransley Hospice</td>
</tr>
</tbody>
</table>
| Consultation and Communication with Stakeholders including public and patient group involvement | Medicines management Committee - meeting 7.12.12
Palliative care clinical governance group – meeting 27.11.12 |
| Archiving Arrangements and register of documents | The Risk Management Team is responsible for the archiving of this policy and will hold archived copies on a central register |
| Equality Analysis (including Mental Capacity Act 2007) | See MMP001 - Control of Medicines Policy |
| Training Needs Analysis | See section 7 |
| Monitoring Compliance and Effectiveness | See section 8 |
| Meets national criteria with regard to | |
| NHSLA | N/A |
| NICE | N/A |
| NSF | N/A |
| Mental Health Act | N/A |
| CQC | N/A |
| Other | N/A |
| Further comments to be considered at the time of ratification for this policy (i.e. national policy, commissioning requirements, legislation) | N/A |
| If this policy requires Trust Board ratification please provide specific details of requirements | N/A |
2. INTRODUCTION
Painful wounds often present a therapeutic challenge in palliative care. Management usually requires treatment with systemic opioids, but their use is commonly complicated by unpredictable bioavailability of the drug within the wound microenvironment due to impaired circulation caused by malignant infiltration of blood vessels supplying the skin. Systemic opioids can also lead to unfavourable side effects.

The hypothesis that opioids exert a local analgesic effect is based on several observations:

- Nociceptive afferent nerve fibres contain peripheral opioid receptors which are silent except in the presence of local inflammation.
- Morphine and its metabolites are largely undetectable systemically when applied topically to skin ulcers, suggesting the analgesic effect is local.
- Peripheral opioid injections for local analgesia, such as intra-articular morphine after knee surgery, have been found to be effective in several trials.

An effective topical opioid analgesic that could be applied to inflamed or open skin lesions would be a useful option for some patients where other options for pain relief have been exhausted.

3. PURPOSE
This guidance has been developed to aid local healthcare professionals working in the specialist field of palliative care to:

- safely evaluate and use topical morphine for painful skin ulcers
- enable them to gain experience in its use
- gather useful audit data
- ensure that this is done in the safest and most standardised way

4. DEFINITIONS
CD – Controlled drug

TTO – To take out (discharge) form

NHFT - Northamptonshire Healthcare NHS Foundation Trust

5. DUTIES

5.1. The Medicine Management Committee
Will approve and review these guidelines
5.2. Unit Managers
Are responsible for ensuring staff have read, understood and adhered to the guideline. It is also their responsibility to ensure all necessary equipment and medication related to the guideline is available and fit for purpose.

5.3. Doctors
Are responsible for assessing uncontrolled wound pain and prescribing any treatment required as appropriate.

5.4. Nursing staff
Are responsible for identifying patients who have uncontrolled wound pain and bringing them to the attention of the doctor.

6. PROCESS

6.1. Inclusion Criteria
All patients MUST be reviewed by a member of the specialist palliative care team - see Appendix 1 for treatment algorithm;
- Terminal or palliative care patients only, with the aim of symptom management rather than wound healing, whose pain remains uncontrolled
- Painful superficial chronic wounds <10cm diameter
- Non-neuropathic, localised pain
- Opioid naive patients - only where the introduction of systemic opioids would be inappropriate, or is refused by the patient
- Opioid tolerant patients - only where side effects prevent adequate dose escalation of the systemic opioid dose

6.2. Exclusion Criteria
- Hypersensitivity (e.g. rash) to morphine or other opioid derivatives
- Hypersensitivity to Intrasite® gel
- Hypersensitivity to propylene glycol
- More than 2 wounds of <10cm diameter
- Any wound greater than 10cm diameter
- Age <18yrs old

6.3. Cautions
- Intolerance to the systemic side effects of morphine or other opioid derivatives
- Severe renal impairment or severe hepatic impairment – reduced doses may actually be used in preference to systemic treatments for this very reason. Monitor carefully for signs of opioid accumulation and toxicity over time
6.4. Contraindications
- Heavily bleeding or exuding wounds (due to reduced ability of the Intrasite® gel to stick to the wound surface)
- Concomitant use of MAO-inhibitors or within 14 days after discontinuation of MAO-inhibitors

6.5. Adverse Effects
Very few side effects have been reported in the literature regarding the use of transdermal morphine. However, the potential exists for systemic absorption, especially over large areas or with higher concentrations. Patients should be closely monitored for opioid side effects, especially if taking opioids orally/topically at the same time.

Some patients complain of pruritus with application of the morphine gel. Intrasite® gel contains propylene glycol, which has been reported to be a potential irritant and sensitizing agent in a small number of patients.

6.6. Guidelines for the Use of Topical Morphine

Please note this is an unlicensed indication.

All prescribing and administration of medications must comply with MMP001 - Control of Medicines Policy. Appendix 2 details the treatment procedure.

6.6.1. Prescribing
For topical morphine the following needs to be prescribed:

“Morphine sulphate 10mg in Intrasite® gel 8g”

For inpatient areas this will be prescribed on the drug chart. If to be continued on discharge a CD TTO form should be completed. In primary care CD requirements need to be met according to the Control of Medicines Policy.

6.6.2. Dose and frequency of application
Initially apply not more than 10mg of morphine in 8g Intrasite® gel (this gives a 0.125% preparation) to cover each painful wound once daily for up to 24 hours, directly onto the wound bed. The amount
of gel applied varies according to the size and the site of the wound but is typically 5 - 8 grams (equivalent to 5-8ml) which should be assessed and monitored by the palliative care team. The Intrasite® gel should be washed off the wound with sodium chloride 0.9% before reapplying the next dose as detailed in Appendix 2.

6.6.3. Secondary dressing
Use foam adhesive dressing according to Northamptonshire Dressings Formulary over the wound and Intrasite® gel/morphine mixture. If a foam dressing is not appropriate, then appropriate formulary film dressing may be used.

6.6.4. Monitoring
Initially patients should be monitored twice daily, using pain scores to measure any improvement from baseline. If there has been no response after 3 - 7 days, treatment should be discontinued. Monitor for signs of opioid accumulation and toxicity, especially in patients with renal/hepatic impairment. Continue topical opioids unless contraindications arise or suitable long term arrangements can be made i.e. nerve block. During use consider frequency of application i.e. could be reduced to alternate days or increased to twice daily. Also consider reducing the systemic analgesia if topical treatment is effective and continue to review effectiveness regularly.

6.6.5. Preparation
Refer to Appendix 2 for instructions on how to prepare.

No commercially manufactured product for morphine 0.125% in Intrasite® gel is available in the UK. In some areas pharmacy manufacturing units can compound the gel as 1 mg preservative-free morphine sulphate per gram of Intrasite® gel on a 'named patient basis' but this is not available locally. Obtaining supplies through this route, especially from manufacturers other than NHS hospitals is very expensive.

6.6.6. Stability
The morphine component has been shown to be stable for up to 28 days when mixed with a neutral water-based hydrogel with no detectable breakdown products. However, when manufactured in any other place than a pharmacy compounding unit, once mixed the gel should be used immediately and not stored. This is due to concerns of microbiological contamination following mixing in a non-sterile environment, rather than the physical instability of the mixed gel.
6.6.7. Disposal
The NHFT Control of Medicines Policy covers the disposal of controlled drugs in detail, and the advice below reflects this guidance. The information below was correct at the time of writing, but staff must ensure they are continually familiar with the most up to date version of the Control of Medicines Policy, which is hosted on the intranet.

Used dressings should be placed in a small sharps bin which is to be kept in an appropriate designated area. Please contact pharmacy for advice. The bin needs to be labelled ‘contains mixed pharmaceutical waste and sharps.’ Prior to disposal, waste CD dressings that have been used on a patient should be folded in half. The clinician must wear gloves.

7. TRAINING

7.1. Mandatory Training
There is no mandatory training associated with this policy.

7.2. Specific Training not covered by Mandatory Training
Ad hoc training sessions based on an individual’s training needs as defined within their annual appraisal or job description.

8. MONITORING COMPLIANCE WITH THIS DOCUMENT
The table below outlines the Trusts’ monitoring arrangements for this document. The Trust reserves the right to commission additional work or change the monitoring arrangements to meet organisational needs.

<table>
<thead>
<tr>
<th>Aspect of compliance or effectiveness being monitored</th>
<th>Method of monitoring</th>
<th>Individual responsible for the monitoring</th>
<th>Monitoring frequency</th>
<th>Group or committee who receive the findings or report</th>
<th>Group or committee or individual responsible for completing any actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duties</td>
<td>To be addressed by the monitoring activities below.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effectiveness of prescribing</td>
<td>Audit</td>
<td>Palliative Care Pharmacist</td>
<td>Annual</td>
<td>Palliative Care Clinical Governance Group</td>
<td>Medicines Management Group</td>
</tr>
</tbody>
</table>

Where a lack of compliance is found, the identified group, committee or individual will identify required actions, allocate responsible leads, target completion dates and ensure an assurance report is represented showing how any gaps have been addressed.
9. REFERENCES AND BIBLIOGRAPHY


10. RELATED TRUST POLICY
• MMP001 – Control of Medicines Policy
APPENDIX 1 – TREATMENT ALGORITHM

PATIENT WITH PALLIATIVE DIAGNOSIS with localised pain to wound or fungating tumour

Systemic analgesics commenced & titrated (prolonged release and breakthrough) as per WHO analgesic ladder & local guidelines

Pain remains uncontrolled
Systemic analgesics causing dose-limiting side effects
Focus of care is on symptom management rather than wound healing
* REFER TO SPECIALIST PALLIATIVE CARE TEAM *

Consider prescribing daily topical application of 10mg Morphine Sulphate in 8g Intrasite Gel directly to wound bed (see treatment procedure)

Pain reduced

Review after 7 days

Pain not reduced

Stop use of topical morphine and consider alternative options

Continue applications of topical morphine.
Consider
* Could applications be reduced to alternate days?
* Should applications be increased to twice daily?
* Could systemic analgesics be reduced?

Continue topical morphine unless
* Contra-indications arise (see protocol)
* Patient does not wish to continue with treatment
* Suitable long term alternatives are arranged (e.g. Nerve block)
* Topical analgesia no longer required

NOTE:
Patients undergoing radiotherapy should wash off any topical preparation within treatment field prior to radiotherapy dose

The current version of any policy, procedure, protocol or guideline is the version held on the NHFT internet. It is the responsibility of all staff to ensure that they are following the current version.
APPENDIX 2 – TREATMENT PROCEDURE

EQUIPMENT REQUIRED

- Sterile dressing pack – containing; plastic tray, apron, gloves, gauze swabs, sterile field, disposable bag
- 0.9% sodium chloride for irrigating/cleaning wound
- Appropriate foam dressing from wound care formulary
- Intrasite gel 8g
- Morphine Sulphate injection 10mg
- 2ml syringe & filter needle
- Plastic probe for mixing gel and morphine
- Sterile spatula
- Sharps bin

PROCEDURE

1. Check authorisation and appropriate documentation
2. Record pain score as reported by patient
3. Explain and discuss the procedure with the patient and obtain consent to proceed
4. Prepare clean dressing field area as per Trust guidelines.
5. Draw up morphine sulphate 10mg and mix with Intrasite Gel 8g in sterile plastic tray, following relevant CD procedures at all times.
6. Remove old dressing and irrigate/cleanse the wound with saline
7. Note size, appearance, odour and exudate from wound to document in notes
8. Apply Intrasite® gel and morphine solution directly to wound bed or onto dressing
9. Apply secondary dressing to wound
10. Dispose of any remaining mixture and any items which have been in contact with morphine in sharps bin. Refer to section 6.6.7 of the guidance.
11. Check that patient is comfortable and dressing is secure
12. Complete documentation
13. Record pain score 2 hours after dressing change